Antitrust Antitrust

Risk of conflicting remedies is price of doing business, FTC's Slaughter says

By Flavia Fortes
  • 26 Mar 2021 12:43
  • 26 Mar 2021 12:55
Companies should weigh the risk of having conflicting remedies for their transactions in different jurisdictions when planning for their deals, the Federal Trade Commission's acting chair said.

“The risk of conflicting remedies is the price of doing business,” Rebecca Kelly Slaughter said at a virtual conference.*

Slaughter said that while she thinks it’s

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Flavia Fortes

Global Head of Mergers


Flavia writes about merger control, antitrust enforcement and litigation in the U.S. and Brazil. Before joining MLex, Flavia worked as an Antitrust Consultant in the Federal Trade Commission's Office of International Affairs and as a Research Fellow for the American Antitrust Institute. She has written on the intersection of antitrust law and intellectual property law in technology-driven and innovative markets.

Discover MLex

Stay on top of global regulatory developments

TAKE A FREE TRIAL

Latest News